“South African health regulators are working on revised standards for pharmaceutical compounding, including medicines associated with the growing demand for GLP-1 treatments for diabetes and weight management. The review aims to clarify when pharmacies may prepare customised medicines for individual patients and address concerns about compounding practices that resemble large-scale manufacturing.”
South Africa Reviews Rules for Compounded Weight-Loss Medicines Amid Safety and Supply Concerns
South Africa’s review of rules governing compounded medicines has brought renewed attention to a question at the centre of modern pharmacy: how can healthcare professionals prepare treatments for individual patients while ensuring that medicines remain safe, effective and appropriately regulated? The issue is especially visible in the market for GLP-1 medicines, a group of treatments used for type 2 diabetes and, in certain formulations, weight management.
A Reuters report published on 14 October 2026 said South African regulators were developing revised minimum standards and guidelines for pharmaceutical compounding. The work involves the South African Pharmacy Council and the South African Health Products Regulatory Authority, known as SAHPRA. The proposed changes are intended to clarify expectations for pharmacies and address concerns that some compounding operations may be preparing medicines ahead of demand in ways that resemble manufacturing. The report is the latest development in a debate shaped by strong demand for weight-loss treatments and questions about how customised medicines should be supplied.
What pharmaceutical compounding means
Compounding is the preparation of a medicine for a particular patient when an appropriate commercially available product does not meet that person’s clinical needs. Depending on the circumstances and applicable rules, a qualified pharmacy may combine, mix or adjust ingredients to create a suitable formulation. Examples can include a different strength, dosage form or ingredient combination when a prescriber determines that an individual patient requires it.
Compounding is not automatically unsafe, nor is it the same as producing an unapproved medicine for broad commercial sale. Its legitimacy depends on the clinical reason for preparation, the quality of ingredients, the competence of the people involved, the conditions under which the medicine is made and the applicable legal framework. Because compounded products may not undergo the same product-specific assessment as registered medicines, careful controls are particularly important.
Why GLP-1 medicines are in focus
GLP-1 medicines have become prominent because some are used to manage type 2 diabetes and certain products are authorised for chronic weight management. These medicines can affect appetite and blood-glucose regulation, but they are not interchangeable lifestyle products. Appropriate treatment depends on a person’s health, medical history, other medicines and clinical assessment.
Rising demand can put pressure on supply and create commercial incentives for alternatives. When an authorised product is difficult to obtain or expensive, patients may encounter advertisements for compounded versions or seek them through online channels. The regulatory challenge is to distinguish legitimate patient-specific compounding from activity that may bypass the standards expected of pharmaceutical manufacturing and medicine registration.
The Reuters report describes regulators’ concern that pharmacies should not operate as small-scale manufacturers by compounding medicines in anticipation of demand rather than for identified patients. That distinction matters because preparation for a specific clinical need is different from producing stock for a general market. The exact application of rules, however, depends on the final standards and the relevant circumstances.
What regulators are trying to clarify
According to the report, revised minimum standards are expected to be submitted to the Pharmacy Council in February 2027, with publication targeted for March. SAHPRA is expected to update its guidance around the same period. Those dates describe a planned timetable, not a completed regulatory change, and may be subject to adjustment.
Clearer standards could help pharmacists, prescribers, patients and suppliers understand what is permitted, which quality safeguards apply and when a product should be sourced through established registered channels instead. Guidance may also reduce uncertainty for pharmacies that want to meet patient needs without crossing into activities that should be regulated as manufacturing.
The review is taking place amid disputes over the interpretation of existing rules, including litigation involving companies in the weight-loss medicine market. Regulatory disagreements can be complex, and a court case or industry complaint should not be treated as proof that a particular medicine is unsafe or that a party has acted unlawfully. The eventual guidance and any relevant legal decisions will help define the position.
Why quality and consistency matter
A medicine’s safety depends on more than its active ingredient. Strength, purity, sterility where required, storage conditions, packaging, labelling and the accuracy of the dose all affect whether a patient receives the intended treatment. Errors can result in too much or too little medicine, contamination, unexpected side effects or failure to treat the underlying condition.
Compounded products may vary because they are prepared in different settings and may use different ingredients or processes. That does not mean every compounded product is poor quality; it means safeguards and oversight must be proportionate to the risks. Patients should be able to establish who prepared a medicine, who prescribed it, how to use it and whom to contact if a problem arises.
Injectable medicines require particular care because preparation errors or contamination can have serious consequences. Products must be made and handled under suitable conditions, with appropriate controls and traceability. Patients should not attempt to prepare injectable medicines themselves or use products whose source, contents or storage history cannot be verified.
The role of pharmacists and prescribers
Pharmacists are central to ensuring that a compounded medicine is prepared only when there is a sound clinical rationale and that the process meets applicable professional standards. Prescribers must assess whether the treatment is appropriate, explain its expected benefits and risks, and consider other options. Good communication between prescriber and pharmacist helps prevent duplication, dosing mistakes and unsuitable substitutions.
For GLP-1 treatment, a patient should receive advice about the medicine’s purpose, dose escalation where relevant, possible adverse effects and circumstances requiring medical review. The correct product and dose depend on the specific medicine and individual prescription. Patients should not assume that products with similar marketing names or claims contain the same ingredients or have equivalent evidence behind them.
People considering treatment should discuss concerns with a qualified healthcare professional rather than rely on social media testimonials or sellers’ promises. A product promoted as a cheaper or customised alternative may not have the same regulatory status or evidence as an authorised medicine. Patients can ask their pharmacist whether the product is registered, where it came from and whether a clinically appropriate authorised option is available.
Access, affordability and shortages
The demand for weight-management medicines also raises questions about affordability and equitable access. Some patients need GLP-1 medicines for diabetes management, while others may be prescribed an authorised product for weight management under relevant clinical criteria. Strong demand across these groups can complicate supply and make it important that prescribing decisions are based on medical need rather than trends.
When medicines are costly or difficult to obtain, people may be tempted to buy from unverified websites, informal sellers or social media accounts. Such routes can expose them to products that are counterfeit, incorrectly stored, diluted, contaminated or falsely labelled. A low price does not demonstrate quality, and a polished package does not establish authenticity.
Regulation alone cannot resolve every access problem. Reliable supply chains, transparent pricing, responsible prescribing and clear public information are also necessary. If a patient cannot afford or obtain a prescribed medicine, they should contact their prescriber or pharmacist to discuss legitimate alternatives. They should not change the dose, stop treatment or substitute another product without professional advice.
What patients should do now
The reported standards are still being developed, so patients should not assume that the planned changes have already taken effect. Anyone currently using a prescribed medicine should continue to follow their clinician’s instructions and raise concerns directly with the prescribing professional or dispensing pharmacist.
The importance of public communication
Regulatory changes can be difficult for the public to follow, particularly when medicines are widely discussed online. Authorities and healthcare professionals should explain what compounding is, why certain practices may be restricted and how patients can access legitimate care. Clear information can reduce confusion without creating unnecessary fear about all customised medicines.
The issue also highlights the importance of transparent accountability. Patients need a clear route for asking questions and reporting suspected quality problems. Pharmacists and prescribers need guidance that is practical enough to apply in everyday practice. Regulators need a framework that protects patients while allowing clinically justified compounding where it is lawful and appropriate.
What happens next
The planned review could establish a clearer line between individualised pharmacy preparation and manufacturing for wider distribution. Its impact will depend on the detail of the standards, how they are communicated, how consistently they are enforced and whether patients can still access appropriate treatment. The proposed dates should be treated as targets until the authorities confirm publication.
For the healthcare sector, the challenge is to balance flexibility with safeguards. A patient may occasionally need a customised formulation, but convenience or market demand alone should not replace clinical justification, quality assurance and regulatory compliance. Registered medicines remain an important option when they are appropriate and available, while compounding must be handled within the limits of professional practice and the law.
For patients, the most useful immediate step is to make treatment decisions with qualified professionals and obtain medicines through trustworthy, authorised channels. Ask questions about registration, ingredients, dosage and storage; do not rely on online popularity as proof of safety. Anyone experiencing a problem should contact a healthcare professional and report concerns through appropriate official channels.
South Africa’s review is therefore not simply a debate about weight-loss injections. It is a broader test of how the medicine system responds when demand rises faster than established supply and when customised products attract commercial interest. Clear rules can help protect patients, support responsible pharmacy practice and give the public a more reliable basis for deciding which treatments to trust.
This article is for news and public information, not individual medical advice. Treatment decisions should be made with a qualified healthcare professional, and prescribed medicines should not be started, stopped or changed without appropriate guidance.
